Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Generic oncology drugs: are they all safe?
Yang YT, Nagai S, Chen BK, Qureshi ZP, Lebby AA, Kessler S, Georgantopoulos P, Raisch DW, Sartor O, Hermanson T, Kane RC, Hrushesky WJ, Riente JJ, Norris LB, Bobolts LR, Armitage JO, Bennett CL. Yang YT, et al. Among authors: qureshi zp. Lancet Oncol. 2016 Nov;17(11):e493-e501. doi: 10.1016/S1470-2045(16)30384-9. Lancet Oncol. 2016. PMID: 27819247 Review.
Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, Lu ZK, Love BL, Noxon V, Bobolts L, Armitage M, Bian J, Ray P, Ablin RJ, Hrushesky WJ, Macdougall IC, Sartor O, Armitage JO. Bennett CL, et al. Among authors: qureshi zp. Lancet Oncol. 2014 Dec;15(13):e594-e605. doi: 10.1016/S1470-2045(14)70365-1. Epub 2014 Nov 24. Lancet Oncol. 2014. PMID: 25456378 Free PMC article. Review.
Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).
Sabol RA, Noxon V, Sartor O, Berger JR, Qureshi Z, Raisch DW, Norris LB, Yarnold PR, Georgantopoulos P, Hrushesky WJ, Bobolts L, Ray P, Lebby A, Kane RC, Bennett CL. Sabol RA, et al. Cancer Med. 2017 Jul;6(7):1541-1551. doi: 10.1002/cam4.1098. Epub 2017 Jun 20. Cancer Med. 2017. PMID: 28635055 Free PMC article. Review.
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).
Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW, Silver S, Murday AS, Armitage JO, Goldsmith D. Bennett CL, et al. Among authors: qureshi zp. Semin Thromb Hemost. 2012 Nov;38(8):783-96. doi: 10.1055/s-0032-1328884. Epub 2012 Oct 30. Semin Thromb Hemost. 2012. PMID: 23111861 Free PMC article. Review.
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
Noxon V, Knopf KB, Norris LB, Chen B, Yang YT, Qureshi ZP, Hrushesky W, Lebby AA, Schooley B, Hikmet N, Dickson M, Thamer M, Cotter D, Yarnold PR, Bennett CL. Noxon V, et al. Among authors: qureshi zp. J Oncol Pract. 2017 Jun;13(6):e562-e573. doi: 10.1200/JOP.2016.019364. Epub 2017 May 15. J Oncol Pract. 2017. PMID: 28504901 Free PMC article.
Editorial Comment.
Qureshi Z, Hrushesky W, Bennett C. Qureshi Z, et al. Urology. 2016 Jul;93:74-5. doi: 10.1016/j.urology.2016.02.059. Epub 2016 May 11. Urology. 2016. PMID: 27179946 No abstract available.
72 results